Maree A. Milross

Nasal versus full face mask for noninvasive ventilation in chronic respiratory failure

This study was undertaken to determine the efficacy of nasal mask (NM) versus full face mask (FFM) for the delivery of noninvasive ventilation (NIV) in subjects with nocturnal hypoventilation. A total of 16 patients (11 males) were enrolled, all with nocturnal hypoventilation currently treated at home with NIV via pressure preset devices. Subjects underwent full polysomnography on three occasions; on the first night current therapy on NM was reviewed, followed by two experimental studies in randomised order using either NM or FFM. NIV settings and oxygen flow rate were the same under both conditions. Notably, 14 of the 16 subjects required the use of a chinstrap to minimise oral leak. Apnoea-hypopnoea indices were within normal limits under both conditions (1.7±3.4 NM versus 1.6±2.4 h FFM). The type of interface did not significantly affect gas exchange during sleep (minimum average arterial oxyhaemoglobin saturation total sleep time 93.4±2.1 NM versus 92.8±2.5% FFM, Delta transcutaneous carbon dioxide nonrapid eye movement sleep to rapid eye movement sleep (0.58±0.36 NM versus 0.50±0.40 kPa FFM). Sleep efficiency was significantly reduced on the FFM (78±9 NM versus 70±14% FFM), although arousal indices were comparable under both conditions (15.6±9.8 NM versus 15.8±8.8 h FFM). Full face masks appear to be as effective as nasal masks in the delivery of noninvasive ventilation to patients with nocturnal hypoventilation. However, a chinstrap was required to reduce oral leak in the majority of subjects using the nasal mask.

Night-to-night variability in sleep in cystic fibrosis

OBJECTIVES The impact of night-to-night variability (NNV) on polysomnography (PSG) has been reported mainly in normal subjects, the elderly and patients with obstructive sleep apnea with focus on changes in the apnea/hypopnea index, rather than measures of nocturnal oxygenation. There is very limited data on NNV in patients with cystic fibrosis (CF). The goal of this study was to assess for first-night effect and reliability of PSG measurements on nocturnal oxygenation and respiratory disturbance in CF. METHODS A prospective observational study was performed in patients with CF who consented to PSG on two consecutive nights. Paired t-tests and intra-class correlation coefficients (ICCs) were calculated for repeated measures of sleep stage time, sleep efficiency, arousal indices, measures of nocturnal oxygenation, and respiratory events in all sleep stages. RESULTS Thirty-one patients with CF were studied, aged 27+/-8 (mean+/-1 SD) years and forced expiratory volume in 1 s (FEV(1)) of 37+/-11% of predicted. Relative to the first-night PSG, on the second PSG, we observed the following: shorter latency to rapid eye movement (REM) sleep (P<0.001), increased sleep efficiency (P<0.01), decreased wake after sleep onset (WASO) time (P<0.01), decreased percentage of non-REM time with oxyhemoglobin saturation by pulse oximetry (SpO(2))< or =90% (P<0.05), decreased number of central apneas per hour (P<0.05) and reduced respiratory rate in stage 2 sleep on night 2 (P<0.05). Despite these changes, the ICCs between night 1 and night 2 showed good repeatability/reliability for measures of nocturnal oxygenation and indices of respiratory disturbance, including the percentage of total sleep time with SpO(2)< or =90% (ICC=0.85) and apnea-hypopnea index (ICC=0.75). Likewise, the ICCs were extremely high for respiratory rate in stage 2 (ICC=0.94), slow wave sleep (ICC=0.97), and REM sleep (ICC=0.96). CONCLUSION Although a first-night effect is seen with sleep efficiency, REM latency, and WASO, a single-night PSG in patients with CF yields reliable information on nocturnal oxygenation and respiratory disturbance.

Sleep-disordered Breathing Before and After Lung Transplantation

BACKGROUND Sleep-disordered breathing (SDB) is common in patients with severe chronic respiratory failure, but there are no data describing the prevalence of SDB among patients listed for lung transplantation or the effect of transplantation on SDB. We sought to determine the prevalence and impact of SDB before and after lung transplantation. METHODS We performed polysomnography (PSG) on 117 of 183 (64%) consecutive patients (64 males, 53 females) listed for lung transplantation between 1998 and 2001. SDB was defined as respiratory disturbance index (RDI) >or=10 or an awake oxygen saturation >90% and >or=10% of total sleep time (TST) with oxygen saturation (SaO2) <or=90%. Room-air PSG was repeated post-transplant in 25 subjects. RESULTS Eighty of 117 patients had PSG on room air, 30 of 117 on oxygen and 7 of 117 on non-invasive ventilation. Thirty two of 80 patients (40%) with room-air PSG had SDB: 18 of 32 (56%) had >or=10% of TST with SaO2 <or=90% and RDI <10, and 14 of 32 (44%) had RDI >or=10. Eight of 32 had both >or=10% of TST with SaO2 <or=90% and RDI >or=10. Nine of 30 (30%) patients on oxygen and 1 of 7 on NIV had SDB. Post-transplant, SDB resolved in 6 of 11 patients with the condition, but 4 of 14 without previous SDB developed new SDB. SDB (treated or not) did not influence whether patients survived to transplant (p = 0.8), nor did a diagnosis of SBD prior to transplant influence post-transplant survival (p = 0.7). CONCLUSIONS SDB is common before lung transplantation. Lung transplantation improves oxygenation, but new-onset SDB may occur after the procedure.

Pressures and Oscillation Frequencies Generated by Bubble-Positive Expiratory Pressure Devices

BACKGROUND: Positive expiratory pressure (PEP) devices are used to assist with airway clearance. Little is known about the therapist-made or commercially available bubble-PEP devices. The aim of this study was to determine the end-expiratory pressures (cm H2O) and oscillation frequencies (Hz) generated when a range of flows were applied to the therapist-made bubble-PEP devices (Bubble-PEP-3cm and Bubble-PEP-0cm) and commercial bubble-PEP devices (AguaPEP, Hydrapep, and Therabubble). METHODS: This was a bench-top experimental study using a compressed air source, flow rotameter (flows of 5, 10, 15, 20, and 25 L/min), and pressure transducer. Data were collected using a data acquisition device with PhysioDAQxs software and analyzed with Breathalyser software to determine the pressures and oscillation frequencies generated by 5 bubble-PEP devices. Each flow was constant for a 30-s measurement period, and measurements were repeated in triplicate. The 5 devices were: a therapist-made Bubble-PEP-3cm device (filled with 13 cm of water, tubing resting 3 cm from the base of the container); the therapist-made Bubble-PEP-0cm (filled with 10 cm of water, tubing resting at the base of the container); and the AguaPEP, Hydrapep, and Therabubble devices with water to the 10 cm mark on the containers. RESULTS: Flows of 5–25 L/min produced the following mean ± SD PEP and oscillation frequencies (Hz): the Bubble-PEP-3cm produced PEP of 10.4 ± 0.14 to 10.8 ± 0.24 cm H2O, oscillations between 13 and 17 Hz; the Bubble-PEP-0cm produced PEP of 10.9 ± 0.01 to 12.9 ± 0.08 cm H2O, oscillations between 12 and 14 Hz; the AguaPEP produced PEP from 9.7 ± 0.02 to 11.5 ± 0.02 cm H2O, oscillations between 11 and 17 Hz; the Hydrapep produced PEP of 9.6 ± 0.35 to 10.7 ± 0.39 cm H2O, oscillations between 14 and 17 Hz; and the Therabubble produced PEP from 8.6 ± 0.01 to 12.8 ± 0.03 cm H2O, oscillations between 14 and 17 Hz. CONCLUSIONS: Bubble-PEP-3cm maintained the most stable pressure throughout the range of flows tested. All devices investigated produced similar oscillation frequencies.

Tubing internal diameter affects the pressures and oscillation frequencies generated by the therapist-made bubble-positive expiratory pressure device

ABSTRACT Objectives: To determine the positive expiratory pressures (PEP) and oscillation frequencies generated in the therapist-made-bubble-PEP device using tubing with different internal diameters (IDs). Design: Bench-top experimental study. Therapist-made-bubble-PEP device with a 10 cm column height of water, tubing length of 30 cm with distal end of the tubing resting 3 cm from base of container. Tubing with 2, 4, 5, 7, 8, and 10 mm IDs were tested with flows of 5, 10, 15, 20, and 25 L/min. A pressure transducer measured the pressures and oscillation frequencies. Data were captured with PhysioDAQxs© software and analyzed with Breathalyser© software. Results: Therapist-made-bubble-PEP device with: (1) 2 mm ID tubing with 5 and 10 L/min flows produced mean(SD) PEP of 20.1(0.2) and 41.8(0.5)cmH2O, respectively, oscillation frequencies of 15-19 Hz; (2) 4 mm ID tubing with 5 and 25 L/min flows produced PEP of 12.5(0.2) and 41.5(0.3)cmH2O, oscillations of 14–18 Hz; (3) 5 mm ID tubing with 5 and 25 L/min flows produced PEP of 10.9(0.1) and 15.8(0.1)cmH2O, oscillations of 17–18 Hz; (4) 7 mm ID tubing with 5 and 25 L/min flows produced PEP of 10.7(0.0) and 12.7(0.2)cmH2O, oscillations of 14–17 Hz; (5) 8 mm ID tubing with 5 and 25 L/min flows produced PEP of 10.5(0.0) and 11.4(0.0)cmH2O, oscillations of 14–18 Hz; and (6) 10 mm ID tubing with 5 and 25 L/min flows produced PEP of 10.4(0.1) and 10.8(0.2)cmH2O, oscillations of 13–17 Hz. Conclusions: Therapist-made-bubble-PEP device with tubing of 10 mm ID generated the most stable PEP in relation to water height (10 cm) irrespective of flow compared to tubing with ID of 2, 4, 5, 7, and 8 mm. The oscillation frequencies generated at all flows and tubing IDs were between 13 and 19 Hz.

Physiotherapy mobility and walking management of uncomplicated coronary artery bypass graft (CABG) surgery patients: a survey of clinicians’ perspectives in Australia and New Zealand

ABSTRACT Background: This study aimed to determine current mobility and walking management by physiotherapists of patients undergoing coronary artery bypass graft (CABG) surgery, the clinical milestones expected and physiotherapists’ perception of the severity of pain experienced by patients after surgery. Design: Cross sectional study using a questionnaire. Methods: All hospitals in Australia and New Zealand that perform cardiac surgery (n = 54) were invited to complete a questionnaire. Findings: Forty-one questionnaires were returned and analysed (response rate 76%). Walking distance was a clinical milestone after CABG surgery. Walking and transferring patients from bed to chair required the most time of physiotherapists during one treatment session. Physiotherapists perceived that patients experienced most pain on day one after surgery [mean (SD)] visual analogue scale (VAS) 41 (16) mm and this reduced by day four to VAS 15 (10) mm. Patients’ pain was perceived to be significantly higher after physiotherapy sessions compared with before (p < 0.01). Thirty-seven respondents (90%) believed that patients’ pain was well managed for physiotherapy treatments. A majority of the respondents (68%) believed that pain was not a limiting factor in the distance patients walked in a physiotherapy session and most (90%) believed that general fatigue limited walk distance. Conclusion: This research provides current mobility and walking management by physiotherapists of patients undergoing CABG surgery in Australia and New Zealand.

Effect of Continuous Local Anesthetic in Post–Cardiac Surgery Patients: A Systematic Review

Objective The purpose of this review was to determine the effect of CLA infusion post cardiac surgery on pain, time to ambulation, severe adverse events, patient satisfaction, time to extubation, length of stay in the intensive care unit and in the hospital, total narcotic consumption, and pulmonary function. Design Systematic review with meta-analysis (PROSPERO CRD42014010188). Methods We searched the following electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL); MEDLINE; EMBASE; CINAHL; Allied and Complementary Medicine (AMED); and PsycINFO; as well as hand-searching cardiothoracic surgery and anesthetic journals and meeting abstracts. Results Ten eligible trials with a total of 546 participants were identified. Meta-analyses showed that CLA infusion significantly reduced the total mean visual analog pain score at 72 hours (mean difference [MD] = -14.31 mm, 95% confidence interval [CI] = -25.59 to -3.03); time to ambulation (MD = -2.81 hours, 95% CI = -5.23 to -0.4); morphine requirement (MD = -10.19 mg, 95% CI = -11.80 to -8.58) but did not reduce time to ambulate to chair (MD = -1.65 hours, 95% CI = -4.04 to 0.74); time to extubation (MD = -0.18 hours, 95% CI = -1.24 to 0.89); length of ICU stay (MD = 0.9 hours, 95% CI = -2.96 to 4.75); and hospital length of stay (MD = -0.59 days, 95% CI = -1.24 to 0.07). There were insufficient data to perform a meta-analysis on severe adverse events, patient satisfaction, or pulmonary function. Conclusions CLA infusion after cardiac surgery reduces pain score at 72 hours, shortens time to ambulation, and reduces morphine consumption at 48 hours.

Does continuous infusion of local anaesthesia improve pain control and walking distance after coronary artery bypass graft surgery? A randomised controlled trial

OBJECTIVES To evaluate the effects of continuous infusion of ropivacaine compared to sham infusion or usual care on pain scores before and after physiotherapy treatment, distance walked and time to discharge from physiotherapy, after coronary artery bypass graft (CABG) surgery. DESIGN Prospective, randomised, double blind controlled trial. SETTING AND PARTICIPANTS Seventy-five participants who underwent CABG surgery with left internal mammary artery grafts were allocated, to the ropivacaine group (n=26), the sham group (n=25), or usual care group (n=24). Participants in the ropivacaine group received 0.5% ropivacaine and participants in the sham group received normal saline, both as continuous infusions via two parasternally tunnelled catheters for 96hours continuously. The usual care group did not receive a device. All groups had patient-controlled analgesia and/or oral analgesia. RESULTS Seventy-two participants completed the study. There was no significant between-group differences in pain scores, distance walked on any post operative day (POD) or number of participants discharged from physiotherapy by POD 4. For the group as a whole there was a significant linear decrease in pain score from mean (SD) 42 (24) mm on POD1 to 15 (16) mm on POD4 (p<0.001), (MD 27mm, 95% CI 22 to 32) and walking distance increased from 1 (5) m on POD1 to 183 (239) m on POD4 (p<0.001) MD 181m, 95% CI 126 to 236). CONCLUSION Infusion of ropivacaine post CABG surgery was unable to reduce pain, increase distance walked or reduce time to physiotherapy discharge compared to sham or usual care. Trial registration number ACTRN12612001243808.